San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

aTyr Pharma Announces Completion of $73 Million Series E Financing

San Diego-based aTyr Pharma Inc., a biotherapeutics firm that treats diseases of the immune system, announced the completion of a $76 million Series E financing on Tuesday.

Tom Cannell Joins Orexigen as Chief Commercial Officer

Orexigen Therapeutics Inc. has hired Tom Cannell has as its chief commercial officer, according to a recent news release.

Teva Acquiring Auspex Pharmaceuticals for $3.2 Billion

Teva Pharmaceutical Industries Ltd. is buying San Diego-based Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on treatments for central nervous system conditions, according to a recent news release.

Tease photo

Executive Q&A: Faheem Hasnain, Receptos

As Faheem Hasnain walks me through rooms of glass and metal, I can’t help but compare the Receptos headquarters to pictures I’ve seen of the Google complex. Pingpong tables and shuffleboard tournaments are held frequently in the biotech’s break-room, and a king-sized chalkboard stands in the corner with winners and losers scratched in white chalk.

Firm Sees Old Drug in New Light Through Genetic Sequencing

BIOTECH: Kura Can Count on Its Cash and Experienced Leaders

A team of veteran drug hunters at Kura Oncology Inc. has licensed an old drug for new purposes, hoping to use advances in genetic sequencing to match the right drug with the right patient.

Tease photo

BioNano Appoints Terry Salyer as Chief Commercial Officer

BioNano Genomics Inc., a genome mapping company in San Diego, announced the appointment of Terry Salyer as chief commercial officer.

CORRECTION: Mast Therapeutics Files New Shelf S-3 Registration Statement

CORRECTION: Mast Therapeutics Inc., a San Diego-based biopharmaceutical company, filed a new “shelf” S-3 registration statement totaling $166.6 million on March 24.

UCSD Health System in Talks with Rancho Mirage Hospital

The UC San Diego Health System is in talks with Eisenhower Medical Center in the Coachella Valley to form a partnership that could potentially lead to the expansion of the Rancho Mirage hospital into a teaching and research hospital, according to The Desert Sun newspaper and a UCSD spokesman.

Retrophin Closes $149.5 Million Public Offering

Retrophin Inc. announced the closing of its previously announced underwritten public offering of 7,866,000 shares of its common stock at a price to the public of $19 per share, including 1,026,000 shares sold pursuant to the full exercise of the underwriters’ option.

Biocept to Collaborate With UCSD Moore Cancer Center

Biocept Inc., a San Diego-based molecular oncology diagnostics company, announced Tuesday that it has entered into a clinical collaboration with the University of California, San Diego Moores Cancer Center.

MEI Pharma's Cancer Drug Pracinostat Fails Phase 2 Trials

Shares of MEI Pharma Inc. lost more than two-thirds of their value Monday after the San Diego biotech said its cancer drug Pracinostat failed a Phase 2 clinical trial.

Tease photo

Mark Harrison Named CFO of UCSD Health Sciences

Mark Harrison has been appointed chief financial officer for UC San Diego Health Sciences, overseeing a budget of more than $2.4 billion for the university.

As Patient Demand Grows, Sharp Rees-Stealy Plans Expansion

Continued population growth in the North County inland region has motivated Sharp Rees-Stealy Medical Center in Rancho Bernardo to announce plans to move to a new facility, nearly doubling the size of the existing medical center.

Batu Biologics Publishes Data on Therapeutic Vaccine

San Diego-based Batu Biologics Inc. announced the publication of pre-clinical data for its flagship immunotherapeutic product, ValloVax in the Journal of Translational Medicine.

Tease photo

Vital Therapies Reports Q4 Results

San Diego-based Vital Therapies Inc., a company developing a cell-based therapy to help people suffering from serious liver disease, announced its fourth quarter financial results on March 19, reporting a net loss of about $14 million compared with a net loss of $10.2 million in the same quarter of 2013.